© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
ESMO clinical recommendations |
Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
1 Breast/Gynecologic Cancer Center and Department of Medical Oncology, Inselspital, Bern
2 Institute of Social and Preventive Medicine (ISPM), University of Geneva, Geneva, Switzerland
* Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland; E-mail: clinicalrecommendations@esmo.org
| The first 10% of the full text of this article appears below. |
 |
incidence |
|---|
The crude incidence of ovarian cancer in the European Union is 18, the mortality is 12/100 000 women/year. The median age at diagnosis is 63 years. The incidence increases with age and peaks in the eighth decade.
|
diagnosis |
|---|
The definitive diagnosis of epithelial ovarian cancer requires a surgical specimen. Pathological diagnosis should be made according to the WHO classification. Established subtypes are: serous, mucinous, endometrioid, clear cell, transitional cell, mixed and undifferentiated carcinomas.
|
staging and risk assessment |
|---|
Surgical staging requires a median laparotomy with a thorough examination of the abdominal cavity according to Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) classification guidelines. If disease appears confined to the ovary, biopsy of the
|
treatment plan |
|---|
early stage disease, FIGO stage I and IIa
advanced disease, FIGO stage IIb–IIIc
advanced disease, FIGO stage IV
|
response evaluation |
|---|
|
follow-up |
|---|
|
recurrent disease |
|---|
|
note |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?